MISSISSAUGA, Ontario, July 16, 2016 /PRNewswire/ — Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (“Aralez” or even the “Organization”), today introduced the outcomes of the issues voted upon in the Firm’s 2016 yearly general meeting (the “Assembly”) of shareholders (the “Investors”) used earlier today, including the selection of administrators, as explained below.
The sum total quantity of common shares of the Organization (“Common Stocks”) displayed by Investors contained in individual or displayed by proxy in the Assembly was a combination of 49,371,169, addressing 77.12% of the Business’s released and outstanding Common Stocks.
Based on proxies obtained along with a vote by poll, the voting leads to regard of every of the next ten representative nominees, all whom formerly offered as administrators of the Organization, were the following:
Each one of the additional issues submit before Investors for thought and acceptance in the Assembly, as explained within the Firm’s proxy statement dated May 6, 2016, was appropriately authorized from the required quantity of ballots.
About Aralez Drugs Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is just a worldwide niche pharmaceutical organization centered on providing significant items to enhance individuals’ lifestyles while making shareholder-value by obtaining, creating and commercializing products mainly in aerobic, discomfort along with other niche areas. Aralez’s International Headquarters is in Ontario, Europe, the U.S. Headquarters is prepared to stay Princeton, NJ and also the Irish Headquarters is in Dublin, Ireland. Extra information about Aralez are available at www.aralez.com.
Aralez Drugs US Inc. Contact:
Nichol M. Ochsner
Executive Director, Investor Relations & Corporate Communications
SUPPLY Aralez Pharmaceuticals Inc.